Stock Analiz

Actinium Pharmaceuticals, Inc. ATNM

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.64Market cap $52M
Open the interactive analysis →

Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare company listed in the US with a market value of about $52M. In the twelve months to June 30, 2026 it had revenue of $35M and net income of $11M, a net margin of 32.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 4.6, a 5-year average ROIC of -109%.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2021 to $90000 in 2025, a decline of about 47.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 23471% of revenue on research and development.

Score: 1.0 / 5

Value2/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)4.6
Forward P/E—
P/FCF—
P/S1.5
P/B1.7
EV/EBITDA1.7
PEG—
Dividend yield0.00%
FCF yield-47.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-25823.1%
ROIC (5-yr avg.)-109.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$35M$90000—$81000$1M$1M—————
Net income$11M-$34M-$38M-$49M-$33M-$25M-$22M-$22M-$24M-$27M-$24M
Free cash flow—-$25M-$33M-$47M$8M-$21M-$22M-$22M-$21M-$22M-$21M
EPS (diluted)$0.36$-1.09$-1.27$-1.83$-1.37$-1.20$-1.83$-4.40$-6.60$-12.00$-15.00
Net margin32.2%-37652.2%—-60269.1%-3205.5%-2165.6%—————
ROIC—-300.9%-97.0%-88.4%-34.0%-24.9%-26.8%-241.8%-207.7%-155.5%-117.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Actinium Pharmaceuticals’s P/E ratio?

About 4.6, based on the last twelve months of diluted earnings per share.

Does Actinium Pharmaceuticals pay a dividend?

Not currently.

Is Actinium Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Actinium Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.